Johnson & Johnson announced the presentation of comprehensive new clinical and real-world data across its industry-leading neuropsychiatry portfolio at Psych Congress 2026. The findings span key therapeutic areas, including major depressive disorder (MDD), treatment-resistant depression (TRD), bipolar I disorder mania, and schizophrenia, reinforcing the company’s commitment to addressing urgent unmet needs in psychiatric medicine.
The data presented underscore critical clinical advancements designed to improve symptom remission, reduce hospitalization rates, and optimize patient adherence across complex, chronic mental health conditions. Key clinical highlights include long-term follow-up analyses and real-world studies evaluating sustained efficacy, rapid reductions in depressive symptoms, and functional recovery patterns for individuals with hard-to-treat depression.Robust clinical evidence assessing therapeutic rapid onset, symptom control, and safety profiles in patients experiencing acute manic episodes associated with bipolar I disorder.Real-world observational data and prospective trials highlighting the therapeutic value of long-acting injectable (LAI) regimens in reducing treatment discontinuation, lowering acute relapse rates, and supporting community reintegration.
With millions of individuals globally living with severe psychiatric disorders, these data sets aim to empower clinicians with actionable insights to personalize care plans and overcome barriers associated with conventional oral therapies, including daily medication non-adherence and breakthrough symptoms.
Johnson & Johnson continues to expand its neurosciences pipeline and research programs, leveraging innovative biological targets and novel formulation technologies to transform treatment paradigms for individuals affected by complex mental illnesses worldwide.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
